Summit Therapeutics (NASDAQ:SMMT) Stock Gets Downgrade from Wall Street Zen

Summit Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Summit Therapeutics from “hold” to “sell.” Other analysts remain more positive overall: MarketBeat reports a “Moderate Buy” consensus and an average price target of $28.10.
  • Shares were reported down 5.9%, opening at $9.95, near the stock’s 12-month low of $9.89.
  • Summit is a clinical-stage cancer drug developer whose lead candidate, ivonescimab, is being evaluated in trials for multiple cancer types.
  • MarketBeat previews the top five stocks to own by December 1st.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms also recently issued reports on SMMT. UBS Group reissued a "neutral" rating on shares of Summit Therapeutics in a research note on Wednesday, September 23rd. Leerink Partners raised shares of Summit Therapeutics from an "underperform" rating to a "market perform" rating and increased their price objective for the stock from $12.00 to $13.00 in a research report on Wednesday, August 12th. Stifel Nicolaus dropped their target price on shares of Summit Therapeutics from $45.00 to $38.00 and set a "buy" rating for the company in a report on Friday, July 24th. HC Wainwright reissued a "buy" rating on shares of Summit Therapeutics in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Summit Therapeutics in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.10.

Check Out Our Latest Stock Report on Summit Therapeutics

Summit Therapeutics Trading Down 5.9%

NASDAQ SMMT opened at $9.95 on Friday. Summit Therapeutics has a twelve month low of $9.89 and a twelve month high of $29.23. The stock has a fifty day simple moving average of $15.74 and a 200-day simple moving average of $16.03.

Institutional Trading of Summit Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Summit Therapeutics in the 2nd quarter valued at approximately $138,838,000. Bellevue Group AG grew its stake in shares of Summit Therapeutics by 13,733.9% in the third quarter. Bellevue Group AG now owns 2,113,681 shares of the company's stock worth $35,742,000 after acquiring an additional 2,098,402 shares in the last quarter. Candriam S.C.A. increased its position in shares of Summit Therapeutics by 212.3% during the third quarter. Candriam S.C.A. now owns 1,662,969 shares of the company's stock worth $28,224,000 after acquiring an additional 1,130,537 shares during the period. Bank of America Corp DE purchased a new stake in shares of Summit Therapeutics during the second quarter worth $12,603,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Summit Therapeutics by 34.4% during the first quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company's stock worth $11,240,000 after acquiring an additional 151,857 shares during the period. 4.61% of the stock is currently owned by hedge funds and other institutional investors.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Further Reading

Analyst Recommendations for Summit Therapeutics (NASDAQ:SMMT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Summit Therapeutics Right Now?

Before you consider Summit Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.

While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines